Literature DB >> 22068627

Caenorhabditis elegans as an experimental tool for the study of complex neurological diseases: Parkinson's disease, Alzheimer's disease and autism spectrum disorder.

Fernando Calahorro1, Manuel Ruiz-Rubio.   

Abstract

The nematode Caenorhabditis elegans has a very well-defined and genetically tractable nervous system which offers an effective model to explore basic mechanistic pathways that might be underpin complex human neurological diseases. Here, the role C. elegans is playing in understanding two neurodegenerative conditions, Parkinson's and Alzheimer's disease (AD), and a complex neurological condition, autism, is used as an exemplar of the utility of this model system. C. elegans is an imperfect model of Parkinson's disease because it lacks orthologues of the human disease-related genes PARK1 and LRRK2 which are linked to the autosomal dominant form of this disease. Despite this fact, the nematode is a good model because it allows transgenic expression of these human genes and the study of the impact on dopaminergic neurons in several genetic backgrounds and environmental conditions. For AD, C. elegans has orthologues of the amyloid precursor protein and both human presenilins, PS1 and PS2. In addition, many of the neurotoxic properties linked with Aβ amyloid and tau peptides can be studied in the nematode. Autism spectrum disorder is a complex neurodevelopmental disorder characterised by impairments in human social interaction, difficulties in communication, and restrictive and repetitive behaviours. Establishing C. elegans as a model for this complex behavioural disorder is difficult; however, abnormalities in neuronal synaptic communication are implicated in the aetiology of the disorder. Numerous studies have associated autism with mutations in several genes involved in excitatory and inhibitory synapses in the mammalian brain, including neuroligin, neurexin and shank, for which there are C. elegans orthologues. Thus, several molecular pathways and behavioural phenotypes in C. elegans have been related to autism. In general, the nematode offers a series of advantages that combined with knowledge from other animal models and human research, provides a powerful complementary experimental approach for understanding the molecular mechanisms and underlying aetiology of complex neurological diseases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22068627     DOI: 10.1007/s10158-011-0126-1

Source DB:  PubMed          Journal:  Invert Neurosci        ISSN: 1354-2516


  131 in total

Review 1.  The biology and pathology of the familial Parkinson's disease protein LRRK2.

Authors:  William Dauer; Cherry Cheng-Ying Ho
Journal:  Mov Disord       Date:  2010       Impact factor: 10.338

2.  Sir-2.1 modulates 'calorie-restriction-mediated' prevention of neurodegeneration in Caenorhabditis elegans: implications for Parkinson's disease.

Authors:  Pooja Jadiya; Manavi Chatterjee; Shreesh Raj Sammi; Supinder Kaur; Gautam Palit; Aamir Nazir
Journal:  Biochem Biophys Res Commun       Date:  2011-08-26       Impact factor: 3.575

Review 3.  Behavioural phenotyping assays for mouse models of autism.

Authors:  Jill L Silverman; Mu Yang; Catherine Lord; Jacqueline N Crawley
Journal:  Nat Rev Neurosci       Date:  2010-07       Impact factor: 34.870

4.  Tetracycline and its analogues protect Caenorhabditis elegans from β amyloid-induced toxicity by targeting oligomers.

Authors:  Luisa Diomede; Giuseppe Cassata; Fabio Fiordaliso; Monica Salio; Diletta Ami; Antonino Natalello; Silvia Maria Doglia; Ada De Luigi; Mario Salmona
Journal:  Neurobiol Dis       Date:  2010-07-14       Impact factor: 5.996

5.  Neurexin-1 is required for synapse formation and larvae associative learning in Drosophila.

Authors:  Xiankun Zeng; Mingkuan Sun; Li Liu; Fading Chen; Liuchan Wei; Wei Xie
Journal:  FEBS Lett       Date:  2007-05-04       Impact factor: 4.124

6.  Neurodegeneration and defective neurotransmission in a Caenorhabditis elegans model of tauopathy.

Authors:  Brian C Kraemer; Bin Zhang; James B Leverenz; James H Thomas; John Q Trojanowski; Gerard D Schellenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-18       Impact factor: 11.205

7.  Disruption of neurexin 1 associated with autism spectrum disorder.

Authors:  Hyung-Goo Kim; Shotaro Kishikawa; Anne W Higgins; Ihn-Sik Seong; Diana J Donovan; Yiping Shen; Eric Lally; Lauren A Weiss; Juliane Najm; Kerstin Kutsche; Maria Descartes; Lynn Holt; Stephen Braddock; Robin Troxell; Lee Kaplan; Fred Volkmar; Ami Klin; Katherine Tsatsanis; David J Harris; Ilse Noens; David L Pauls; Mark J Daly; Marcy E MacDonald; Cynthia C Morton; Bradley J Quade; James F Gusella
Journal:  Am J Hum Genet       Date:  2008-01       Impact factor: 11.025

Review 8.  Roles of amyloid precursor protein and its fragments in regulating neural activity, plasticity and memory.

Authors:  Paul R Turner; Kate O'Connor; Warren P Tate; Wickliffe C Abraham
Journal:  Prog Neurobiol       Date:  2003-05       Impact factor: 11.685

9.  In vivo aggregation of beta-amyloid peptide variants.

Authors:  D S Fay; A Fluet; C J Johnson; C D Link
Journal:  J Neurochem       Date:  1998-10       Impact factor: 5.372

Review 10.  A synaptic trek to autism.

Authors:  Thomas Bourgeron
Journal:  Curr Opin Neurobiol       Date:  2009-06-21       Impact factor: 6.627

View more
  28 in total

1.  egl-4 modulates electroconvulsive seizure duration in C. elegans.

Authors:  Monica G Risley; Stephanie P Kelly; Justin Minnerly; Kailiang Jia; Ken Dawson-Scully
Journal:  Invert Neurosci       Date:  2018-05-30

2.  Mass Histology to Quantify Neurodegeneration in Drosophila.

Authors:  Elizabeth R Sunderhaus; Doris Kretzschmar
Journal:  J Vis Exp       Date:  2016-12-15       Impact factor: 1.355

3.  Exposure of C. elegans eggs to a glyphosate-containing herbicide leads to abnormal neuronal morphology.

Authors:  Kenneth A McVey; Isaac B Snapp; Megan B Johnson; Rekek Negga; Aireal S Pressley; Vanessa A Fitsanakis
Journal:  Neurotoxicol Teratol       Date:  2016-03-26       Impact factor: 3.763

Review 4.  Biochemistry, function, and deficiency of vitamin B12 in Caenorhabditis elegans.

Authors:  Tomohiro Bito; Fumio Watanabe
Journal:  Exp Biol Med (Maywood)       Date:  2016-08-02

Review 5.  C. elegans as a model in developmental neurotoxicology.

Authors:  Joanna A Ruszkiewicz; Adi Pinkas; Mahfuzur R Miah; Rebecca L Weitz; Michael J A Lawes; Ayodele J Akinyemi; Omamuyovwi M Ijomone; Michael Aschner
Journal:  Toxicol Appl Pharmacol       Date:  2018-03-14       Impact factor: 4.219

Review 6.  Using C. elegans to decipher the cellular and molecular mechanisms underlying neurodevelopmental disorders.

Authors:  Carlos Bessa; Patrícia Maciel; Ana João Rodrigues
Journal:  Mol Neurobiol       Date:  2013-03-14       Impact factor: 5.590

7.  An ancestral non-proteolytic role for presenilin proteins in multicellular development of the social amoeba Dictyostelium discoideum.

Authors:  Marthe H R Ludtmann; Grant P Otto; Christina Schilde; Zhi-Hui Chen; Claire Y Allan; Selina Brace; Philip W Beesley; Alan R Kimmel; Paul Fisher; Richard Killick; Robin S B Williams
Journal:  J Cell Sci       Date:  2014-01-24       Impact factor: 5.285

8.  Neuroligin modulates the locomotory dopaminergic and serotonergic neuronal pathways of C. elegans.

Authors:  Patricia G Izquierdo; Fernando Calahorro; Manuel Ruiz-Rubio
Journal:  Neurogenetics       Date:  2013-10-08       Impact factor: 2.660

Review 9.  Caenorhabditis elegans as a Model to Study the Molecular and Genetic Mechanisms of Drug Addiction.

Authors:  Eric A Engleman; Simon N Katner; Bethany S Neal-Beliveau
Journal:  Prog Mol Biol Transl Sci       Date:  2015-11-24       Impact factor: 3.622

10.  Chronic exposure to a glyphosate-containing pesticide leads to mitochondrial dysfunction and increased reactive oxygen species production in Caenorhabditis elegans.

Authors:  Denise C Bailey; Callie E Todt; Shelbie L Burchfield; Aireal S Pressley; Rachel D Denney; Isaac B Snapp; Rekek Negga; Wendy L Traynor; Vanessa A Fitsanakis
Journal:  Environ Toxicol Pharmacol       Date:  2017-11-20       Impact factor: 4.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.